This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sastre-Garriga, J Articles by Montalban, X Search for Related Content PubMed PubMed Citation Articles by Sastre-Garriga, J Articles by Montalban, X Social Bookmarking                         What's this?

Decreased MMP-9 production in primary progressive multiple sclerosis patients

Unitat de Neuroimmunologia Clínica, Hospital Vall d’Hebron, Barcelona, Espanya, jsastre{at}hg.vhebron.es

M Comabella

Unitat de Neuroimmunologia Clínica, Hospital Vall d’Hebron, Barcelona, Espanya

L Brieva

Unitat de Neuroimmunologia Clínica, Hospital Vall d’Hebron, Barcelona, Espanya

A Rovira

Unitat de Ressonància Magne`tica, Hospital Vall d’Hebron, Barcelona, Espanya

M Tintoré

Unitat de Neuroimmunologia Clínica, Hospital Vall d’Hebron, Barcelona, Espanya

X Montalban

Unitat de Neuroimmunologia Clínica, Hospital Vall d’Hebron, Barcelona, Espanya

Background: An increase in MMP-9 levels has been found in relapsing-remitting (RR) multiple sclerosis (MS) showing correlation with magnetic resonance (MR) parameters mainly during relapses. However, data regarding primary progressive (PP) MS is scarce. Objectives: To determine both the pro and active forms of MMP-9 in PPMS and transitional progressive (TP) MS, RRMS and healthy controls (HC), and to assess the relationship between MMP-9 levels and clinical and radiological variables in PP/TPMS. Methods: 73 patients with PP/TPMS, 50 RRMS and 43 HC were studied. Levels of pro and active forms of MMP-9 in serum were measured with ELISA. EDSS and MSFC scores were recorded and T2- and T1-weighted MR scans were obtained at the time of blood sampling and one and two years later for PP/TP MS cases. Results: MMP-9 levels were 202.27 ng/ml for PP/TPMS, 242.20 ng/ml for RRMS and 274.49 ng/ml for HC. MMP-9 levels were significantly lower in PP/TPMS compared to RRMS(P-0.026) and HC (P- 0.001). No significant correlations were found between MMP-9 levels and clinical scores or radiological parameters. Conclusions: These results point to different regulatory mechanisms of MMP-9 production and/or activity between PP/TPMS and RRMS.

Key Words: blood-brain barrier • MMP-9 • multiple sclerosis • primary progressive

Multiple Sclerosis, Vol. 10, No. 4, 376-380 (2004)
DOI: 10.1191/1352458504ms1058oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Koch, J. Mostert, A. Arutjunyan, M. Stepanov, A. Teelken, D. Heersema, and J. De Keyser Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis Multiple Sclerosis, March 1, 2008; 14(2): 159 - 165. [Abstract] [PDF]

				M. Ukkonen, X. Wu, B. Reipert, P. Dastidar, and I. Elovaara Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 701 - 707. [Abstract] [PDF]

				F. Mannello, G.A.M. Tonti, and F. Canestrari The `never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples Multiple Sclerosis, June 1, 2007; 13(5): 687 - 690. [PDF]

				E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 294 - 301. [Abstract] [PDF]